Atrial fibrillation: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R00

  Emotional and biobehavioral mechanisms of parent-infant emotional synchrony

  Children's Hosp of Philadelphia· Philadelphia, United States· US$248,999 awarded in fiscal year 2026· until Aug 2029

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, United States· US$40,326 awarded in fiscal year 2026· until Jul 2028

• NIH NINR · R01

  SCH: Integrated AI and Sensing Systems for Mitigating Heart Failure Readmissions in High-Risk Groups with Obesity

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$1,200,000 awarded in fiscal year 2026· until Aug 2030

• NIH NIA · R43

  A Smart Remote Monitoring System for Cardiometabolic Management in Patients with Alzheimer's and Related Dementia

  Aventusoft, Llc· Boca Raton, United States· US$500,000 awarded in fiscal year 2026· until Sept 2027

• NIH NINDS · R56

  Characterizing a Calcium Channel Causing FASP: Examining Entrainment Changes as a Mechanism for Phase Advance

  University of California, San Francisco· San Francisco, United States· US$574,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until Aug 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Sweden· EU contribution €252,180· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spain· EU contribution €209,915· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Israel· EU contribution €3,375,000· until Dec 2031

10 of 792 running projects, newest first. Listed amounts together: US$470.8m + €148.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 222
• Genome-Wide Association Study 62

• Joint non-linear dose-response associations of device-measured physical activity and cardiorespiratory fitness with cardiovascular disease: a cohort and Mendelian randomisation study.

  Br J Sports Med, Aug 2026

• Cross-population proteome-wide mendelian randomization study identifies likely causal proteins for cardiovascular diseases.

  Mol Genet Genomics, Aug 2026

• Integrative multi-omics reveals a fibroblast-centered, ZFHX3-prioritized regulatory framework linking sick sinus syndrome and atrial fibrillation.

  Cell Signal, Aug 2026

• Meta-Analysis of Genome-Wide Association Studies of Doxorubicin-Induced Arrhythmia Identifies MMP16 and KCTD15 as Risk Loci.

  Circ Genom Precis Med, Jul 2026

• Genetic susceptibility to uric acid and selected cardiovascular outcomes: a systematic review and meta-analysis of Mendelian randomization studies.

  Front Endocrinol (Lausanne), Jul 2026

• Integrative Observational and Genetic Evidence From the UK Biobank Supports Carotid Intima-Media Thickness as a Window Into Cardiac Remodeling.

  J Am Heart Assoc, Jul 2026

• SLIT2 and ANGPTL3 as putative mediators linking obesity to atrial fibrillation: A Mendelian randomization study.

  Medicine (Baltimore), Jul 2026

• The causal relationships and potential pathways between birth weight and cardiovascular diseases: A human genomics study.

  Medicine (Baltimore), Jun 2026

• Multiomics Insights Into the Role of Spondin-1 in the Pathogenesis and Prognosis of Atrial Fibrillation.

  J Am Heart Assoc, Jun 2026

• Integrated Genomic and Transcriptomic Analysis Reveals the Genetic Basis and Causal Association Between Obesity and Atrial Fibrillation.

  Diabetes Obes Metab, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.